Ciba-Geigy
Executive Summary
Richard Barth, 54, to president and chief exec officer of Ciba-Geigy Corp., the U.S. subsidiaries of the Swiss firm. He succeeds Otto Sturzenegger, who is stepping down after 15 years on April 1. Barth is moving up from the role of chief financial officer for the U.S. operations. Charles O'Brien, 55, is moving to exec-VP and chief operating officer on April 1, succeeding A. M. MacKinnon. O'Brien has been president of U.S. Pharmaceuticals for three years.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.